Sinovac BiotechSVA
13F holders, Q3 2024 (September 30)9holders −17
0new positions
18sold out
$28.05avg. 13F price*
At the end of Q3 2024, 9 institutions reported holding Sinovac Biotech Ltd. (SVA) in their 13F filings, down 17 from Q2 2024. 0 opened new positions and 18 sold out. The largest holders were Orbimed Advisors LLC ($340.0M), Vivo Capital, LLC ($76.3M) and Neumann Advisory Hong Kong Ltd ($2.0M).
- Company
- Sinovac Biotech Ltd.
- CUSIP
- P8696W104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 18 | $1.2M |
All 13F filers, Q2 2024 → Q3 2024: 5 shares bought and 1,456,234 shares sold, net −1,456,229 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Orbimed Advisors LLC | 6.22% | No change | 2,718,735 | $340.0M |
| Vivo Capital, LLC | 6.32% | No change | 11,800,000 | $76.3M |
| Neumann Advisory Hong Kong Ltd | 0.83% | No change | 315,586 | $2.0M |
| Horizon Investments, LLC | 0.00% | No change | 52 | $336 |
| Navellier & Associates Inc. | 0.00% | No change | 14,167 | $0 |
| California Public Employees Retirement System | 0.00% | No change | 68,732 | $0 |
| Assetmark, Inc. | 0.00% | Add +31.3% | 21 | $0 |
| Financial Gravity Companies, Inc. | 0.00% | — | 24 | $0 |
| Transamerica Financial Advisors, LLC | 0.00% | No change | 2 | $0 |
"% of holder's portfolio" is SVA's weight in each manager's 13F, not the share of Sinovac Biotech Ltd. the manager owns.